Ranbaxy signs licensing pact with EPIRUS Switzerland

The pact is for a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).

 

New Delhi, January 9, 2014: Ranbaxy Laboratories has inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA). It is important to note that EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals Inc.

 

The product will be introduced in India and other emerging markets and there is no biosimilar of Infliximab approved in India, the company said in a statement.

 

As per the terms of the agreement, EPIRUS will develop and supply the product and post securing the required approvals, Ranbaxy will market the same in India and other emerging markets. 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...